Mologen, Onco Life Sciences Pvt. Ltd., Synvolux deal

Onco Life Sciences received a non-exclusive license in India to develop and commercialize MGN's cell-based gene-therapy to treat renal cell carcinoma (RCC) and colon, breast and lung cancers. MGN received E2.1 million ($2.8 million) up front. The gene therapy is expected to enter Phase I/II testing to treat RCC this year. ...